Black Diamond's second quarter was, in one sentence, a clinical-stage single-asset story writing itself onto the page. Silevertinib - the company's brain-penetrant fourth-generation EGFR inhibitor - produced a 60% objective response rate, an 86% central nervous system (CNS) response rate in patients with baseline brain metastases, and a 15.2-month preliminary median progression-free survival in 43 frontline non-classical EGFR-mutant non-small cell lung cancer (NSCLC) patients at the American Society of Clinical Oncology (ASCO) Annual Meeting in May, and no patient in the dataset developed de novo brain metastases. The quarter's accounting, by contrast, was the cleanest possible version of a clinical-stage biotech: zero revenue, $12.1 million of operating expenses, and a $9.9 million net loss, against a $110.5 million cash position that the company says is sufficient to fund operations into the second half of 2028. The market is treating BDTX as a single readout in a single drug, with two questions the next nine months must answer: does the U.S. Food and Drug Administration (FDA) accept the 150-milligram once-daily dose as a pivotal path, and does the randomized Phase 2 glioblastoma (GBM) trial of silevertinib plus temozolomide reach its first interim this year? At a $2.02 reference price, the equity is paying for those two questions, not for the next four years of operating expenditures.